Exploratory Phase 0/1 of Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs ODS 2004436 (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Diagnostic use; First in man
- 18 Dec 2017 According to an Oncodesign media release, first stage of this study has been completed with promising results and full results are expected in the first half of 2018.
- 20 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.
- 20 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.